PacBio Raises $20.6M through Common Stock Sale in H1 2014 | GenomeWeb

NEW YORK (GenomeWeb) – Pacific Biosciences raised $20.6 million in net proceeds through the sale of 3 million shares of its common stock during the first half of 2014, the company disclosed in its Form 10-Q filed with the US Securities and Exchange Commission on Monday.

PacBio said it sold the stock at an average price of $7.12 per share in an at-the-market offering, a type of offering in which shares are offered at the prevailing market prices. The firm added that its current at-the-market offering program has about $17.9 million of common shares available for future sales.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.

Mar
30
Sponsored by
SeraCare

Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay. 

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.